Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Which of the following arachidonic acid derivatives is used in the treatment of glaucoma?

Latanoprost. **Explanation:** **Latanoprost** is the correct answer because it is a synthetic **Prostaglandin F2-alpha (PGF2α) analogue**. In the management of glaucoma, PGF2α analogues are considered first-line agents. They work by increasing the **uveoscleral outflow** of aqueous humor, thereby reducing intraocular pressure (IOP). **Analysis of Options:** * **Latanoprost (Option A):** A PGF2α derivative. It is highly effective, requires only once-daily dosing, and has a superior IOP-lowering effect compared to many beta-blockers. * **Iloprost (Option B):** A synthetic analogue of **Prostacyclin (PGI2)**. It acts as a potent vasodilator and inhibitor of platelet aggregation. It is primarily used in the treatment of pulmonary arterial hypertension and Raynaud's phenomenon, not glaucoma. * **Alprostadil (Option C):** A synthetic form of **Prostaglandin E1 (PGE1)**. Its clinical uses include maintaining the patency of the ductus arteriosus in newborns and treating erectile dysfunction. It does not have a role in glaucoma management. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** PGF2α analogues reduce IOP by remodeling the extracellular matrix in the ciliary muscle, enhancing the uveoscleral (non-conventional) pathway. * **Side Effects (High Yield):** 1. **Hypertrichosis:** Increased length and thickness of eyelashes (Bimatoprost is specifically used for this in Latisse). 2. **Iris Pigmentation:** Permanent darkening of the iris (heterochromia) due to increased melanin in melanocytes. 3. **Cystoid Macular Edema (CME):** Can occur in aphakic or pseudophakic patients. 4. **Prostaglandin-associated Periorbitopathy:** Loss of periorbital fat leading to a "sunken eye" appearance. * **Contraindication:** Active intraocular inflammation (uveitis), as prostaglandins are pro-inflammatory mediators.

Q: Which of the following drugs is NOT a centrally acting antagonist used in opioid dependency?

naldemedine. ### Explanation The key to answering this question lies in distinguishing between **centrally acting** and **peripherally acting** opioid antagonists. **1. Why Naldemedine is the correct answer:** Naldemedine is a **PAMORA** (Peripherally Acting Mu-Opioid Receptor Antagonist). It is chemically modified (by adding a side chain) to prevent it from crossing the blood-brain barrier (BBB) [4]. Because it acts only on receptors in the gastrointestinal tract without reversing central analgesia or affecting dependency, it is used specifically for **Opioid-Induced Constipation (OIC)**. It has no role in treating opioid dependency or overdose. **2. Analysis of Incorrect Options:** * **Naloxone (A):** A competitive antagonist at all opioid receptors. It crosses the BBB rapidly but has poor oral bioavailability [1]. It is the drug of choice for **acute opioid overdose** [3]. Additionally, in opioid-dependent patients, it precipitates a withdrawal syndrome [2]. * **Naltrexone (D):** A long-acting central antagonist with good oral bioavailability. It is primarily used for **relapse prevention** in opioid and alcohol dependency [4]. * **Nalmefene (B):** Similar to naltrexone but with a longer half-life [1]. It is used for treating alcohol dependence and, in some regions, opioid overdose [4]. **3. NEET-PG High-Yield Pearls:** * **PAMORAs:** Remember the "3 M's and an N" for Opioid-Induced Constipation: **M**ethylnaltrexone, **M**ovantik (Naloxegol), **M**aluby (Naldemedine), and **A**lvimopan. * **Alvimopan** is specifically used to accelerate bowel recovery after major surgery (Post-operative ileus). * **Naltrexone** is also FDA-approved for **Alcohol Use Disorder** as it reduces the "reward" or craving by blocking endogenous opioid release. * **Naloxone** is often combined with Buprenorphine (Suboxone) to prevent intravenous abuse of the oral formulation [5].

Q: Which of the following is NOT used in the acute management of gout?

Allopurinol. The management of gout is divided into two distinct phases: **Acute Attack Management** (to reduce inflammation) and **Chronic Prophylaxis** (to lower serum uric acid). ### 1. Why Allopurinol is the Correct Answer **Allopurinol** is a xanthine oxidase inhibitor used for **hypouricemic therapy**. It is contraindicated during an acute attack because a rapid fluctuation in serum urate levels can cause the mobilization of urate crystals from tissue stores into the joint space, potentially **worsening or prolonging the acute inflammation**. It should only be started 2–4 weeks after the acute episode has completely resolved. ### 2. Analysis of Incorrect Options * **NSAIDs (e.g., Indomethacin, Naproxen):** These are the first-line agents for acute gout. They work by inhibiting prostaglandin synthesis, thereby reducing pain and inflammation. * **Corticosteroids (e.g., Prednisolone):** Used when NSAIDs or Colchicine are contraindicated (e.g., renal failure). They can be administered orally, intravenously, or intra-articularly. * **Colchicine:** A specific anti-gout drug that inhibits microtubule polymerization and leukocyte migration. It is highly effective if started within 24–36 hours of symptom onset. ### 3. NEET-PG High-Yield Pearls * **Drug of Choice (DOC):** NSAIDs are generally the DOC for acute gout; however, if the patient has peptic ulcer disease or renal insufficiency, **Corticosteroids** are preferred. * **The "Allopurinol Paradox":** If a patient is *already* on Allopurinol when an acute attack starts, do **not** stop it. If they are not on it, do **not** start it. * **Febuxostat:** Another xanthine oxidase inhibitor used for chronic management, preferred in patients with mild-to-moderate renal impairment. * **Aspirin:** Avoid in gout as low doses inhibit uric acid excretion in the tubules, worsening hyperuricemia.

Q: Which of the following statements about Mycophenolate Mofetil is not true?

Most common adverse effect is Nephrotoxicity. **Explanation:** **1. Why Option A is the correct (false) statement:** Mycophenolate Mofetil (MMF) is notably **not nephrotoxic**. This is a high-yield distinction because it is frequently used as a "calcineurin inhibitor-sparing agent" to reduce the dose of drugs like Cyclosporine or Tacrolimus, which are notoriously nephrotoxic. The most common adverse effects of MMF are **gastrointestinal (GI) disturbances** (nausea, vomiting, diarrhea, and abdominal pain) and **myelosuppression** (leukopenia). **2. Analysis of other options:** * **Option B:** MMF is a standard immunosuppressant used to prevent **acute and chronic transplant rejection** (kidney, heart, and liver) and in autoimmune conditions like Lupus Nephritis. * **Option C:** MMF is indeed a **prodrug**. After oral administration, it is rapidly hydrolyzed by esterases in the gut and liver to its active metabolite, **Mycophenolic Acid (MPA)**. * **Option D:** MMF and Azathioprine are both antimetabolites that inhibit purine synthesis. Using them together increases the risk of severe bone marrow suppression without significant therapeutic benefit; hence, they are **not used concurrently**. **Clinical Pearls for NEET-PG:** * **Mechanism of Action:** MMF is a selective, non-competitive, reversible inhibitor of **Inosine Monophosphate Dehydrogenase (IMPDH)**. This inhibits the *de novo* pathway of guanosine nucleotide synthesis. * **Selectivity:** Since T and B lymphocytes rely solely on the *de novo* pathway (unlike other cells that use the salvage pathway), MMF is highly selective for lymphocytes. * **Teratogenicity:** MMF is associated with "Mycophenolate embryopathy" (ear and facial abnormalities); it is contraindicated in pregnancy.

Q: Which of the following is NOT a function of H1 antagonists?

Decrease gastric acid secretion. The correct answer is **C (Decrease gastric acid secretion)** because this function is mediated by **H2 receptors**, not H1 receptors [2]. Histamine acts on different receptor subtypes: * **H1 Receptors:** Located in smooth muscles, endothelium, and the CNS. They mediate allergic inflammation, pruritus, and wakefulness [1], [3]. * **H2 Receptors:** Located primarily on the **gastric parietal cells**. Activation increases cAMP, leading to gastric acid secretion. Therefore, H2 antagonists (e.g., Ranitidine, Famotidine) are used to decrease acid, while H1 antagonists have no effect on this process [2]. **Analysis of other options:** * **A. Antipruritic:** H1 receptors mediate the "itch" sensation in sensory nerve endings. H1 blockers are the mainstay for treating urticaria and allergic pruritus [2], [3]. * **B. Sedation:** First-generation H1 blockers (e.g., Diphenhydramine, Chlorpheniramine) are highly lipophilic and cross the blood-brain barrier. By blocking central H1 receptors involved in arousal, they cause significant sedation [4]. * **D. Antivertigo:** Certain H1 antagonists (e.g., Cinnarizine, Meclizine, Promethazine) have significant anticholinergic and central effects that suppress the vestibular apparatus, making them effective for motion sickness and vertigo. **NEET-PG High-Yield Pearls:** 1. **Second-generation H1 blockers** (e.g., Cetirizine, Loratadine, Fexofenadine) are non-sedating because they have poor CNS penetration and are substrates for the P-glycoprotein efflux pump [1], [4]. 2. **Fexofenadine** is the active metabolite of Terfenadine and is considered the least sedating [1]. 3. **Astemizole and Terfenadine** were withdrawn due to the risk of **Torsades de Pointes** (QT prolongation) when co-administered with CYP3A4 inhibitors (e.g., Ketoconazole, Erythromycin).

Q: Prostaglandin E2 analogs can be used for all of the following conditions EXCEPT:

Treatment of patent ductus arteriosus. The correct answer is **A. Treatment of patent ductus arteriosus**. [1] In fetal life, the ductus arteriosus is kept open by endogenous prostaglandins (PGE2). After birth, if the ductus remains open (Patent Ductus Arteriosus - PDA), it leads to abnormal hemodynamics [2]. To treat PDA, we aim to **close** the shunt by inhibiting prostaglandin synthesis using **NSAIDs** (e.g., Indomethacin or Ibuprofen). Conversely, PGE2 analogs (Alprostadil) are used to *maintain* patency in ductal-dependent congenital heart diseases, not to treat PDA [2]. **Analysis of other options:** * **B. Treatment of bronchial asthma:** While not a first-line agent, PGE2 has bronchodilatory properties. Note that PGF2$\alpha$ and PGD2 are bronchoconstrictors, but PGE2 acts as a vasodilator and bronchodilator. * **C. Cervical priming:** PGE2 analogs like **Dinoprostone** are gold-standard agents used for cervical ripening and induction of labor as they soften the cervix and stimulate uterine contractions [1], [4]. * **D. Treatment of NSAID-induced peptic ulcer:** **Misoprostol** (a PGE1/E2 analog) is cytoprotective [3]. It increases bicarbonate and mucus secretion while decreasing gastric acid production, making it the drug of choice for preventing NSAID-induced ulcers [1], [3]. **High-Yield Clinical Pearls for NEET-PG:** * **PGE1 Analog (Alprostadil):** Used for maintaining ductus patency and erectile dysfunction [1]. * **PGE1 Analog (Misoprostol):** Used for medical abortion (with Mifepristone) and NSAID-induced ulcers [1]. * **PGF2$\alpha$ Analogs (Latanoprost):** First-line for Glaucoma [1]. * **PGI2 Analogs (Epoprostenol):** Used in Pulmonary Hypertension [1].

Q: Naloxone for opioid receptor acts as:

Pure antagonist. **Naloxone** is the prototype **pure opioid antagonist** [1, 2]. It has a high affinity for all three opioid receptors (μ, κ, and δ) but lacks intrinsic activity [1]. It works by competitively displacing opioids from their receptors, thereby reversing all opioid effects, including respiratory depression and sedation [1].* **Why Option B is Correct:** Naloxone is a "pure" antagonist because it produces no pharmacological effect of its own when administered alone [1]. It only acts in the presence of an agonist (like Morphine or Heroin) to block or reverse its action.* **Why Option A is Incorrect:** A pure agonist (e.g., Morphine, Fentanyl) binds to the receptor and produces a maximal functional response.* **Why Option C is Incorrect:** A partial agonist (e.g., Buprenorphine) binds to the receptor but produces a sub-maximal response even at high doses [3].* **Why Option D is Incorrect:** Agonist-antagonists (e.g., Pentazocine, Nalbuphine) act as an agonist at one receptor (usually κ) and an antagonist at another (usually μ).**High-Yield Clinical Pearls for NEET-PG:**1. **Drug of Choice:** Naloxone is the DOC for **acute opioid poisoning** [1].2. **Pharmacokinetics:** It has a very short duration of action (30–90 minutes) and poor oral bioavailability due to extensive first-pass metabolism; hence, it is given IV/IM/Intranasal.3. **Naltrexone vs. Naloxone:** Unlike Naloxone, **Naltrexone** is orally active and long-acting, making it the drug of choice for **preventing relapse** in detoxified opioid addicts and for treating alcohol dependence.4. **Methylnaltrexone:** A peripheral μ-antagonist used specifically for opioid-induced constipation without reversing analgesia [1].

Q: Which of the following drugs can cause oligospermia?

Methotrexate. **Explanation:** **Correct Option: A. Methotrexate** Methotrexate (MTX) is a folic acid antagonist that inhibits the enzyme **dihydrofolate reductase (DHFR)**. This inhibition leads to a depletion of tetrahydrofolate, which is essential for DNA synthesis and cell division. Because spermatogenesis is a process involving rapid cellular proliferation, the testes are highly sensitive to the cytotoxic effects of MTX. It can cause **oligospermia** (low sperm count), reversible infertility, and chromosomal damage in sperm. Clinically, male patients are advised to discontinue MTX at least 3 months before attempting conception. **Analysis of Incorrect Options:** * **B. Hydroxychloroquine:** This is an antimalarial and DMARD used in SLE and RA. It is generally considered safe regarding male fertility and is one of the few DMARDs safe during pregnancy. * **C. Leflunomide:** This drug inhibits **dihydroorotate dehydrogenase**, affecting pyrimidine synthesis. While it is highly teratogenic (Category X) and requires a "washout" procedure with cholestyramine, it is not a classic cause of oligospermia compared to MTX. * **D. D-penicillamine:** A chelating agent used in Wilson’s disease and formerly in RA. Its primary side effects include nephrotic syndrome, pemphigus, and myasthenia-like syndrome, but not oligospermia. **High-Yield Clinical Pearls for NEET-PG:** * **Other drugs causing oligospermia:** Sulfasalazine (very common high-yield fact), Cyclophosphamide (can cause permanent azoospermia), Cimetidine, and Anabolic steroids. * **Sulfasalazine vs. Methotrexate:** Sulfasalazine-induced oligospermia is typically reversible within 2–3 months of discontinuation. * **Rescue Therapy:** Leucovorin (folinic acid) is used to "rescue" normal cells from MTX toxicity but does not always prevent gonadal impact.

Q: Which physiological effect is NOT produced by stimulation of the Kappa opioid receptor?

Constipation. **Explanation:** The correct answer is **Constipation**. While constipation is a hallmark side effect of opioid analgesics, it is primarily mediated by **Mu (μ) receptors** located in the gastrointestinal tract, which decrease motility. Stimulation of **Kappa (κ) receptors** has a negligible effect on bowel motility. **Analysis of Options:** * **Sedation (A):** Kappa receptor stimulation produces significant sedation and dysphoria. Unlike Mu-mediated euphoria, Kappa agonists often cause a "flat" or unpleasant sedative effect. * **Diuresis (B):** This is a high-yield distinction. While Mu receptors cause urinary retention (by increasing sphincter tone), Kappa receptors **inhibit the release of ADH (Vasopressin)** at the posterior pituitary, leading to free water clearance and diuresis. * **Miosis (C):** Both Mu and Kappa receptors contribute to pupillary constriction (miosis) via the stimulation of the Edinger-Westphal nucleus. * **Constipation (D):** As noted, this is a Mu-receptor-mediated effect. Kappa agonists do not significantly delay gastric emptying or cause constipation. **Clinical Pearls for NEET-PG:** * **Receptor Triad:** Remember the "Big Three": **Mu** (Analgesia, Euphoria, Respiratory Depression, Constipation), **Kappa** (Analgesia, Dysphoria, Diuresis, Sedation), and **Delta** (Analgesia, Seizures). * **Dysphoria:** A key differentiator; Mu = Euphoria, Kappa = Dysphoria/Hallucinations. * **Respiratory Depression:** Kappa receptors produce much less respiratory depression compared to Mu receptors, providing a "ceiling effect." * **Mixed Agonist-Antagonists:** Drugs like **Pentazocine** and **Butorphanol** act primarily as Kappa agonists and Mu antagonists/partial agonists.

Question 1

Which of the following statements about immunosuppressants is INCORRECT?

Accepted Answer

Mycophenolate inhibits purine synthesis via GMP dehydrogenase.

Answer

Tacrolimus inhibits the calcineurin pathway.

Answer

Steroids bind to cytosolic receptors and heat shock proteins.

Answer

Sirolimus blocks a kinase in the IL-2 receptor pathway.

Question 2

Which of the following arachidonic acid derivatives is used in the treatment of glaucoma?

Accepted Answer

Latanoprost

Answer

Iloprost

Answer

Alprostadil

Answer

None of the above

Question 3

Which of the following drugs is NOT a centrally acting antagonist used in opioid dependency?

Accepted Answer

naldemedine

Answer

naloxone

Answer

nalmefene

Answer

naltrexone

Question 4

Which of the following is NOT used in the acute management of gout?

Accepted Answer

Allopurinol

Answer

NSAIDs

Answer

Corticosteroids

Answer

Colchicine

Question 5

Which of the following statements about Mycophenolate Mofetil is not true?

Accepted Answer

Most common adverse effect is Nephrotoxicity

Answer

Used in Transplant Rejection

Answer

It is a prodrug and converted to Mycophenolic acid

Answer

Is not used with Azathioprine

Question 6

Which of the following is NOT a function of H1 antagonists?

Accepted Answer

Decrease gastric acid secretion

Answer

Antipruritic

Answer

Sedation

Answer

Antiveigo

Question 7

Prostaglandin E2 analogs can be used for all of the following conditions EXCEPT:

Accepted Answer

Treatment of patent ductus arteriosus

Answer

Treatment of bronchial asthma

Answer

Cervical priming

Answer

Treatment of NSAID-induced peptic ulcer

Question 8

Naloxone for opioid receptor acts as:

Accepted Answer

Pure antagonist

Answer

Pure agonist

Answer

Partial agonist

Answer

Agonist antagonist

Question 9

Which of the following drugs can cause oligospermia?

Accepted Answer

Methotrexate

Answer

Hydroxychloroquine

Answer

Leflunomide

Answer

D-penicillamine

Question 10

Which physiological effect is NOT produced by stimulation of the Kappa opioid receptor?

Accepted Answer

Constipation

Answer

Sedation

Answer

Diuresis

Answer

Miosis

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?